Edwards Lifesciences (NYSE:EW) Upgraded at Evercore ISI


Share on StockTwits

Evercore ISI upgraded shares of Edwards Lifesciences (NYSE:EW) from an in-line rating to an outperform rating in a research note issued to investors on Monday morning, Analyst Price Targets reports.

Several other research firms have also recently commented on EW. Canaccord Genuity boosted their price target on shares of Edwards Lifesciences from $89.00 to $94.00 and gave the company a buy rating in a report on Friday, December 11th. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $93.00 to $98.00 and gave the company an overweight rating in a report on Friday, December 11th. Raymond James upped their price objective on shares of Edwards Lifesciences from $90.00 to $96.00 and gave the stock an outperform rating in a report on Friday, December 11th. Smith Barney Citigroup cut shares of Edwards Lifesciences from a buy rating to a neutral rating in a report on Wednesday, December 16th. Finally, Zacks Investment Research cut shares of Edwards Lifesciences from a hold rating to a sell rating and set a $90.00 price objective for the company. in a report on Tuesday, December 22nd. Three analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company. Edwards Lifesciences has a consensus rating of Hold and a consensus price target of $91.45.

Edwards Lifesciences stock opened at $84.12 on Monday. The company’s fifty day simple moving average is $82.73 and its 200-day simple moving average is $83.59. The company has a quick ratio of 2.61, a current ratio of 3.52 and a debt-to-equity ratio of 0.14. Edwards Lifesciences has a 12 month low of $64.78 and a 12 month high of $92.08. The stock has a market cap of $52.33 billion, a P/E ratio of 67.30, a P/E/G ratio of 2.61 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, January 26th. The medical research company reported $0.50 EPS for the quarter, missing the consensus estimate of $0.53 by ($0.03). Edwards Lifesciences had a net margin of 18.18% and a return on equity of 29.00%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the prior year, the firm earned $1.46 earnings per share. The company’s revenue was up 1.5% on a year-over-year basis. On average, equities research analysts expect that Edwards Lifesciences will post 1.89 earnings per share for the current fiscal year.

In other news, VP Jean-Luc M. Lemercier sold 13,020 shares of the company’s stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $83.66, for a total transaction of $1,089,253.20. Also, Director Nicholas J. Valeriani sold 8,200 shares of the company’s stock in a transaction dated Thursday, February 4th. The shares were sold at an average price of $85.21, for a total transaction of $698,722.00. Following the transaction, the director now directly owns 67,896 shares of the company’s stock, valued at approximately $5,785,418.16. The disclosure for this sale can be found here. Insiders have sold 331,057 shares of company stock valued at $28,117,680 over the last 90 days. Corporate insiders own 1.48% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bainco International Investors acquired a new position in Edwards Lifesciences in the fourth quarter worth about $28,000. Sound Income Strategies LLC raised its position in Edwards Lifesciences by 375.0% in the fourth quarter. Sound Income Strategies LLC now owns 380 shares of the medical research company’s stock worth $35,000 after purchasing an additional 300 shares in the last quarter. Sage Private Wealth Group LLC acquired a new position in Edwards Lifesciences in the fourth quarter worth about $37,000. Earnest Partners LLC raised its position in Edwards Lifesciences by 425.8% in the third quarter. Earnest Partners LLC now owns 510 shares of the medical research company’s stock worth $41,000 after purchasing an additional 413 shares in the last quarter. Finally, Fieldpoint Private Securities LLC acquired a new position in Edwards Lifesciences in the fourth quarter worth about $45,000. 80.94% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Read More: Options Trading

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.